Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Waller is active.

Publication


Featured researches published by J. Waller.


Medical Dosimetry | 2014

Volumetric-modulated arc radiotherapy for pancreatic malignancies: dosimetric comparison with sliding-window intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy.

Nima Nabavizadeh; Anna Simeonova; J. Waller; Jeanna L. Romer; Debra Monaco; David A. Elliott; James A. Tanyi; Martin Fuss; Charles R. Thomas; John M. Holland

Volumetric-modulated arc radiotherapy (VMAT) is an iteration of intensity-modulated radiotherapy (IMRT), both of which deliver highly conformal dose distributions. Studies have shown the superiority of VMAT and IMRT in comparison with 3-dimensional conformal radiotherapy (3D-CRT) in planning target volume (PTV) coverage and organs-at-risk (OARs) sparing. This is the first study examining the benefits of VMAT in pancreatic cancer for doses more than 55.8 Gy. A planning study comparing 3D-CRT, IMRT, and VMAT was performed in 20 patients with pancreatic cancer. Treatments were planned for a 25-fraction delivery of 45 Gy to a large field followed by a reduced-volume 8-fraction external beam boost to 59.4 Gy in total. OARs and PTV doses, conformality index (CI) deviations from 1.0, monitor units (MUs) delivered, and isodose volumes were compared. IMRT and VMAT CI deviations from 1.0 for the large-field and the boost plans were equivalent (large field: 0.032 and 0.046, respectively; boost: 0.042 and 0.037, respectively; p > 0.05 for all comparisons). Both IMRT and VMAT CI deviations from 1.0 were statistically superior to 3D-CRT (large field: 0.217, boost: 0.177; p < 0.05 for all comparisons). VMAT showed reduction of the mean dose to the boost PTV (VMAT: 61.4 Gy, IMRT: 62.4 Gy, and 3D-CRT: 62.3 Gy; p < 0.05). The mean number of MUs per fraction was significantly lower for VMAT for both the large-field and the boost plans. VMAT delivery time was less than 3 minutes compared with 8 minutes for IMRT. Although no statistically significant dose reduction to the OARs was identified when comparing VMAT with IMRT, VMAT showed a reduction in the volumes of the 100% isodose line for the large-field plans. Dose escalation to 59.4 Gy in pancreatic cancer is dosimetrically feasible with shorter treatment times, fewer MUs delivered, and comparable CIs for VMAT when compared with IMRT.


International Journal of Radiation Oncology Biology Physics | 2017

Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment

Nima Nabavizadeh; J. Waller; Robert Fain; Yiyi Chen; Catherine Degnin; David A. Elliott; Brandon T. Mullins; Ishan A. Patel; Brandon A. Dyer; Kareem Fakhoury; Willscott E. Naugler; Khashayar Farsad; James A. Tanyi; Martin Fuss; Charles R. Thomas; Arthur Y. Hung


International Journal of Radiation Oncology Biology Physics | 2013

Outcomes of Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma (HCC)

J. Waller; Willscott E. Naugler; A. Zaman; Susan L. Orloff; Kevin G. Billingsley; G. Vaccaro; Kenneth J. Kolbeck; John A. Kaufman; James A. Tanyi; Martin Fuss


Journal of Clinical Oncology | 2017

Safety and efficacy of accelerated hypofractionation and stereotactic body radiotherapy for hepatocellular carcinoma in the setting of advanced liver dysfunction.

Nima Nabavizadeh; J. Waller; Robert Fain; Yiyi Chen; Catherine Degnin; David A. Elliott; Brandon T. Mullins; Ishan A. Patel; Brandon A. Dyer; Willscott E. Naugler; Khashayar Farsad; James A. Tanyi; Martin Fuss; Charles R. Thomas; Arthur Y. Hung


International Journal of Radiation Oncology Biology Physics | 2016

Safety and Efficacy of Stereotactic Body Radiation Therapy of Accelerated Hypofractionation for Hepatocellular Carcinoma in the Setting of Advanced Liver Dysfunction

Nima Nabavizadeh; J. Waller; R. Fain; Yiyi Chen; David A. Elliott; Brandon T. Mullins; Ishan A. Patel; Catherine Degnin; Brandon A. Dyer; Khashayar Farsad; James A. Tanyi; Martin Fuss; Charles R. Thomas; Arthur Y. Hung


International Journal of Radiation Oncology Biology Physics | 2013

Outcomes of Hypofractionated Radiation Therapy (HFxRT) for Hepatocellular Carcinoma (HCC)

Martin Fuss; J. Waller; S. Naugler; A. Zaman; Kenneth J. Kolbeck; Susan L. Orloff; Kevin G. Billingsley; M. Chang; A. Sasaki; John A. Kaufman


International Journal of Radiation Oncology Biology Physics | 2013

Qualitative and Quantitative Distress Assessment of Cancer Patients Using the NCCN Distress Thermometer

Dustin Boothe; J. Waller; Yiyi Chen; S. Hedlund; Charles R. Thomas


Journal of Clinical Oncology | 2011

Emotional well-being and quality of life in patients undergoing radiation therapy for pancreatic and hepatobiliary malignancies.

B. T. Samuelson; Erik K. Fromme; J. Waller; Charles R. Thomas


Journal of Clinical Oncology | 2011

Quality-of-life measurements in patients receiving radiation therapy for colorectal malignancies as compared to other gastrointestinal malignancies.

B. T. Samuelson; Erik K. Fromme; J. Waller; Charles R. Thomas


International Journal of Radiation Oncology Biology Physics | 2010

Spirituality and Quality of Life in Patients Receiving Radiation Therapy (RT) at a NCI-designated Cancer Center: Preliminary Report from the Knight Cancer Institute Patient-related Outcomes (PRO) Database

B.T. Samuelson; Erik K. Fromme; T.L. McDonald; J. Waller; Clifton D. Fuller; Charles R. Thomas

Collaboration


Dive into the J. Waller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brandon T. Mullins

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge